RecruitingPhase 1NCT05018767
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Aging Frailty
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Aging Frailty
Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Enrollment
86 participants
Start Date
Jan 22, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Aging Frailty
Eligibility
Inclusion Criteria2
- Diagnosis of Aging Frailty
- Understanding and willingness to sign a written informed consent document
Exclusion Criteria10
- Active infection
- Active cancer
- Chronic multisystem organ failure
- Pregnancy
- Clinically significant abnormalities on pre-treatment laboratory evaluation
- Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
- Continued drug abuse
- Pre-menopausal women not using contraception
- Previous organ transplant
- Hypersensitivity to sulfur
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALAlloRx
cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05018767
Related Trials
Plant-based Diets and Healthy Aging
NCT071513651 location
Frailty in Older Adults With Chronic Obstructive Pulmonary Disease (COPD) and Outcomes of the VIVIFRAIL Program
NCT075196032 locations
The Relationship Between Preoperative Frailty and Postoperative AKI and the Mediating Effect of Intraoperative BP
NCT070301791 location
Frailty in Patient Undergoing Percutaneous Left Atrial Appendage Closure.
NCT052579541 location
Prehabilitation in Gynaecological Cancer Patients
NCT047896941 location